2022
NAFTNet retrospective report on the treatment of anti-Ro/SSA mediated fetal heart block with dexamethasone
Sunderji S, Peyvandi S, Jaeggi E, Szwast A, Ryan G, Tessier F, Siddiqui S, Cuneo B, Sheth S, Treadwell M, Frommelt M, Turan S, Copel J, Emery S, Rand L, Moon-Grady AJ, Network F. NAFTNet retrospective report on the treatment of anti-Ro/SSA mediated fetal heart block with dexamethasone. The Journal Of Maternal-Fetal & Neonatal Medicine 2022, 35: 9263-9270. PMID: 35014577, DOI: 10.1080/14767058.2022.2025536.Peer-Reviewed Original ResearchConceptsPositive pregnanciesPrimary outcomePregnancy complicationsPregnancy outcomesPremature deliverySecondary outcomesNorth American Fetal Therapy Network (NAFTNet) centersRo/SSA-positive pregnanciesRetrospective multi-center cohort studyAnti-Ro/SSAMulti-center cohort studyFetal heart blockOverall pregnancy complicationsBetter pregnancy outcomesPoor pregnancy outcomesUse of dexamethasoneTerms of efficacyHigh rateFetal dyadsMaternal comorbiditiesAntibody positivityExpectant managementMaternal diseaseNeonatal morbidityPreterm delivery
2020
Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers
Izmirly P, Kim M, Friedman DM, Costedoat-Chalumeau N, Clancy R, Copel JA, Phoon CKL, Cuneo BF, Cohen RE, Robins K, Masson M, Wainwright BJ, Zahr N, Saxena A, Buyon JP. Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. Journal Of The American College Of Cardiology 2020, 76: 292-302. PMID: 32674792, PMCID: PMC7394202, DOI: 10.1016/j.jacc.2020.05.045.Peer-Reviewed Original ResearchConceptsCongenital heart blockPrimary outcomeSecondary outcomesEndocardial fibroelastosisHeart blockRecurrence of CHBSSA/Ro-positive mothersAnti-SSA/RoMacrophage Toll-like receptorToll-like receptor antagonistsCutaneous neonatal lupusRo-positive mothersGestational weeks 10Toll-like receptorsFetal cardiac diseaseNeonatal lupusPositive mothersSecondary preventionSkin rashPrevious pregnancyTreat analysisClinical evidenceRecurrence rateReceptor antagonistOptimal approach